×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 13: Post-Marketing Safety Regulations – US
Session Chair(s)
Mark Vieder, MBA, RPh
Vice President, Drug Safety and Pharmacovigilance
Biorasi, LLC, United States
This session will cover the FDA requirements for safety reporting for marketed products including prescription products, Abbreviated applications and complaint files as well as nonprescription (OTC) and dietary supplements.
Have an account?